31081-59-1

Usage

InChI:InChI=1/C19H40O3S/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-23(2,20)21/h3-19H2,1-2H3

Upstream product

• 112-92-5 1-octadecanol 
• 124-63-0 methanesulfonyl chloride 
• 1731-94-8 nonadecanoic acid methyl ester 

Downstream Products

• 6297-03-6 19-oxaheptatriacontane 
• 6076-42-2 1,2,3-tri(octadecyloxy)propane 
• 18794-74-6 1,3-bis(octadecyloxy)-2-propanol 
• 6076-38-6 2,3-bis(octadecyloxy)propan-1-ol 
• 638-66-4 n-Octadecanal 
• 56537-19-0 octadecyl hydroperoxide 
• 16725-43-2 4-(n-octadecyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 111004-27-4 (2S,4S)-4-Octadecyloxymethyl-2-phenyl-[1,3]dioxane 
• 82831-88-7 N-(7-Oxapentacosyl)phthalimide 
• 84379-60-2 2-O-benzyl-3,4-O-isopropylidene-1-O-octadecyl-L-threitol 
• 82936-50-3 2-Phenyl-4-<(octadecyloxy)methyl>-2-oxazoline 
• 84379-56-6 1-O-octadecyl-2-O-benzyl-3,4-O-isopropylidene-D-threitol 
• 150844-24-9 (+)-1-O-octadecyl-2-O-methyl-3-O-(4-methoxybenzyl)-sn-glycerol 
• 150844-22-7 1,6-di-O-octadecyl-2,5-di-O-methyl-3,4-bis-O-(4-methoxybenzyl)-D-mannitol 

Relevant academic research and scientific papers

Multicompartment Theranostic Nanoemulsions Stabilized by a Triphilic Semifluorinated Block Copolymer

The presence of a perfluorocarbon block in a multiblock polymer has been shown to be an additional driving force toward nanoparticle assembly. In the preparation of nanoemulsions, this perfluorocarbon block also provides enhanced particle stability. Herei

Enantiomeric synthesis of natural alkylglycerols and their antibacterial and antibiofilm activities

Alkylglycerols (AKGs) are bioactive natural compounds that vary by alkyl chain length and degree of unsaturation, and their absolute configuration is 2S. Three AKGs (5l–5n) were synthesised in enantiomerically pure form, and were characterised for the first time together with 12 other known and naturally occurring AKGs (5a–5k, 5o). Their structures were established using 1H and 13C APT NMR with 2D-NMR, ESI-MS or HRESI-MS and optical rotation data, and they were tested for their antibacterial and antibiofilm activities. AKGs 5a–5m and 5o showed activity against five clinical isolates and P. aeruginosa ATCC 15442, with MIC values in the range of 15–125 μg/mL. In addition, at half of the MIC, most of the AKGs reduced S. aureus biofilm formation in the range of 23%–99% and P. aeruginosa ATCC 15442 biofilm formation in the range of 14%–64%. The antibiofilm activity of the AKGs assessed in this work had not previously been studied.

Stable Theranostic and Therapeutic Nanoemulsions Using Triphilic Semifluorinated Amphiphiles

The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds. Formulations and methods of the invention include semifluorinated block copolymers and an

Synthesis, Physicochemical Characterization, and Self-Assembly of Linear, Dibranched, and Miktoarm Semifluorinated Triphilic Polymers

Linear, dibranched, and miktoarm amphiphiles containing both hydrophobic and fluorophilic moieties were synthesized and characterized in an attempt to elucidate the relationship between semifluorinated amphiphile structure and aggregate behavior in aqueous solution. For the linear and dibranched amphiphiles, there was an exponential decrease in critical aggregation concentration (CMC) and a logarithmic increase in core microviscosity with increasing length of the fluorocarbon segments; while the miktoarm architecture produced no notable trend in microviscosity or CMC. Furthermore, the linear and dibranched surfactants showed enhanced kinetic stability, dissociating more slowly in the presence of human serum than did either the dibranched or miktoarm amphiphiles. Finally, encapsulation studies with the hydrophobic drug paclitaxel (PTX) showed that the ability to solubilize and retain PTX increased with the presence and with the increasing size of the fluorocarbon moiety for both the linear and dibranched amphiphiles, while no such trend was observed for the miktoarm amphiphiles. VC 2014 Wiley Periodicals, Inc.

Lipid Compounds Targeting VLA-4

The invention relates to the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein n, G, W, X, Y, and R1 are defined in the detailed description and claims. The compounds of formula I bind to or associate with VLA-4 and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing VLA-4.

Hypocholesterolemic activity of hesperetin derivatives

Hesperetin ester and ether derivatives possessing a long alkyl chain were synthesized for examining their hypocholesterolemic activities in high cholesterol-fed mice. Hesperetin 7-O-lauryl ether (4b) and hesperetin 7-O-oleyl ether (4e) exhibited strong cholesterol-lowering effects.

D and L etherlipid stereoisomers and liposomes

A liposome having a lipid bilayer, where the lipid bilayer includes either the L or D stereoisomer of an ether lipid or a non-equal mixture of both. Most preferably the liposome also comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine, and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid. The liposome may be used as an anti-cancer or anti-inflammatory agent.

Compositions and methods using novel substituted imidazolium lipids

Compounds of the formula: are provided, in which R1 and R2 each independently represent a C8-C24 saturated or unsaturated hydrocarbon chain, which is optionally interrupted by from 1 to 3 heteroatom moieties, such as -O-, -S-, -NH- and -NR-. The symbol X represents -CH2-, -O-, -S-, -NH- or -NR-. The R group for each of the -NR- moieties represents an alkyl group having from 1 to 4 carbon atoms. Finally, the subscript n represents the integer 1 or 2, and A- represents an anion, preferably chloride or citrate.

Lipopolycationic telomers for gene transfer: Synthesis and evaluation of their in vitro transfection efficiency

We report on the synthesis of a series of lipopolyamine telomers I-14,n, I-18,n, and II-18,n and on their in vitro gene-transfer capability. Their structure consists of a polyamine polar moiety, including n primary amine functions (from 1 to 70), connected to a hydrophobic moiety, including two hydrocarbon C14 or C18 chains, through a mercaptopropanoyl or mercaptoglyceryl unit and an amide or ether function. They were obtained by telomerization of N-{2-[(BOC)-aminoethyl]}acrylamide with N,N-ditetradecyl- and N,N-dioctadecylpropanamide-3-thiol and rac-1,2-dioctadecyloxypropane-3- thiol, respectively, then BOC deprotection. For N/P ratios (N = number of telomer amine equivalents; P = number of DNA phosphates) from 0.8 to 10, these lipopolyamines condensed DNA, with or without the use of DOPE, forming lipopolyplexes or teloplexes of mean sizes less than 200 nm. Some trends, structure-activity and structure-toxicity relationships, were established toachieve both highest in vitro transfection levels and cell viability. Thus, DNA formulations based on telomers I-14,20 and I-18,20 and for N/P ratios lower than 5 led to the most efficient teloplex formulations for plasmid delivery to lung epithelial A549 cells.